KARGER Publishers – Connecting the World of Biomedical Science

Karger Publishers’ Editorial Division Asia (EDA) of experienced professionals is now serving this flourishing region with dedicated offices in Shanghai, Tokyo and Chennai (India).

Karger EDA helps biomedical research experts communicate their findings and increase visibility worldwide.

Karger EDA’s editorial services include:

- Editorial consulting, advising societies and other groups on publishing projects of all types, from classic print book series to eBooks and much more
- Consulting on essential developments in publishing such as Open Access
- Establishing new journals and re-launching existing journals
- Customization of publications to fit strategic marketing concepts
- Helping societies reach audiences in new markets via congresses and other venues
- Consulting for websites
- Expert, skilled staff; up-to-date production and distribution; and a vast editorial network

Transporting your message to key opinion leaders and making you an integral partner for a global readership is our goal.

Contacts:
Basel, Switzerland
Peter Roth  Tel. +41 76 565 3435  p.roth@karger.com

Shanghai, China
Veronica Zhang-Fan  Tel. +86 136 4175 9929  v.zhangfan@karger.asia

Tokyo, Japan
Setsuko Nishihara  Tel. +81 90 8316 3832  senish@karger.jp

Chennai, India
Mizpah  Tel. +91 44 24492511  mizpah@karger.asia
Gastro Intestinal Tumors

Founded 2013 by J.-Y. Fang and P. Malfertheiner

Editors
Jing-Yuan Fang, Shanghai
Peter Malfertheiner, Magdeburg

Editorial Board
Christoph Auernhammer, München
Markus N. Büchler, Heidelberg
Ying-Xuan Chen, Shanghai
Yasuhiro Kodera, Nagoya
Klaus Mönkemüller, Birmingham, Ala.
Goro Nakayama, Nagoya
Yong-Zhan Nie, Xi’an
Gerhard Rogler, Zürich
Masao Tanaka, Fukuoka
Jan J.B. van Lanschot, Rotterdam
Bertram Wiedenmann, Berlin
Kai-Chun Wu, Xi’an
Wei-Fen Xie, Shanghai
Hui-Ping Xue, Shanghai

Appears quarterly:
1 volume per year
(4 issues)
Guidelines for Authors

Submission
The Journal accepts Mini-Reviews which provide overviews of recent key data and therapeutic regimens. An Abstract is required and should be divided into Background, Summary and Key Messages. Manuscripts should be submitted to:

Editorial Office 'Gastrointestinal Tumors'
S. Karger AG
Ms. Tanja Sebuk
PO Box
CH-4009 Basel (Switzerland)
Tel. +41 61 306 1481
Fax +41 61 306 1234
E-Mail t.sebuk@karger.com

All manuscripts must be accompanied by a cover letter and copyright signed by all authors. Assurance should be given in the cover letter that the manuscript is not under simultaneous consideration by any other publication.

Length of Mini-Review
- max. 300 word abstract
- approx. 2,500 words main text
- 1 table
- 2 illustrations
- approx. 25 references

Conditions
All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Gastrointestinal Tumors and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Disclosure Statement
Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Disclosure statements will be published at the end of the text of the article.

Ethics
Published research must comply with the guidelines for human studies and animal welfare regulations. Authors should state that subjects have given their informed consent and that the study protocol has been approved by the institute's committees on human research. Further, they should also state that animal experiments conform to institutional standards. Authors are required to declare the approval codes obtained from the corresponding ethical committee on human and/ or animal research.

Plagiarism Policy
Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and with citation.

If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not satisfactory, the manuscript will be rejected and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Arrangement
The manuscript should conform to the following order: title page, abstract and key words, body, acknowledgments, references, figure legends, tables and figures. Manuscripts should be written in high-quality English suitable for effective communication to a professional medical audience. Authors who are not native speakers of English sometimes receive negative comments from referees or editors about the English-language usage in their manuscripts, and these problems can contribute to the decision to reject a paper. To help reduce the possibility of such problems, we strongly encourage such authors (i) to have their manuscript reviewed for clarity by a colleague whose native language is English and/or (ii) to use one of the many English language editing services that are available via the web. All pages, including the figure legends, should be numbered in sequence, and the first author's name should appear at the upper right corner of each page. Papers not conforming to the journal style will be returned without review.

Title Page: The first page of each paper should indicate a concise title of no more than 150 characters, all authors' names (first name and surname), authors' institutional affiliations, and a short title for use as running head.

Corresponding author: The exact postal address of author(s) to whom correspondence, proofs, and reprint requests should be sent, including the postal code, must be given at the bottom of the title page. Please also supply phone number and e-mail address.

Abstract of Review Articles: Should be divided into the following subheadings: Background, Summary and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review. Submit the abstract on a separate page. The abstract should be less than 300 words.

Key words: Following the abstract, an alphabetical list of five key words that reflect the content of the paper should be given.

Footnotes: Avoid footnotes.

Tables and illustrations: Tables and illustrations (both numbered in sequential Arabic numerals) should be prepared as separate files. Tables require a brief and concise heading. Figures require a legend, prepared as a separate page, after references. Please use scale markers for electron micrographs, and indicate the type of stain used. For the reproduction of illustrations, only good drawings and original photographs can be accepted; negatives or photocopies cannot be used. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 223 mm) or provide crop marks. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples
(a) Papers published in periodicals: Chatel J-M, Bernard H, Orson FM: Isolation and characterization of two complete Arch 2 isoforms cDNA. Int Arch Allergy Immunol 2003;131:14–18.
(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.
(c) Monographs: Matthews DE, Fare-well VT: Using and Understanding Medical Statistics, ed 3, revised. Basel, Karger, 1996.
(d) Edited books: Dubois RN: Cyclooxygenase-2 and colorectal cancer; in Dannenberg AJ, Dubois RN (eds): COX-2. Prog Exp Tum Res. Basel, Karger, 2003, vol 37; pp 124–137.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Author’s Choice™
Karger’s Author’s Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.–, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the review article. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 Mb in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

NIH-Funded Research
The U.S. National Institutes of Health (NIH) mandates that NIH-funded research results are published in the PubMed Central (PMC) database within 12 months of the official publication date, and video files (.mov, .avi, .mpeg).
Guidelines for Authors

upon publication. It usually receives a PMCID within approximately a month and will appear in PMC after 12 months. For those selecting our premium Author’s Choice™ service, the usual embargo will be overridden, accelerating the accessibility of your work.

Self-Archiving
Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution’s servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher’s version, and must acknowledge the publisher’s copyright. Authors selecting Karger’s Author’s Choice™ feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.

Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author.

Reprints
Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

Transforming Vesalius
The medical revolution of the 16th century brought to life for the 21st century

ANDREAS VESALIUS
The Fabric of the Human Body
An Annotated Translation of the 1543 and 1555 Editions of “De Humani Corporis Fabrica” by

DANIEL H. GARRISON
MALCOLM H. HAST

CXX + 1338 p., 340 fig., in two volumes
Hard cover with slip case, 315 × 435 mm, 16 kg
Price: CHF 1,500.– / EUR 1,250.– / USD 1,650.00
ISBN 978–3–318–02246–9

The Fabric of the Human Body compares the translations of the 1543 and the 1555 editions. Annotations and added notes by Vesalius for a never published third edition give the reader keen insight into just how innovative this Renaissance masterpiece was. Because of the modern layout and the new translation, the 21st-century reader is now able to understand the complexity and pioneering nature of this milestone in medical history without the knowledge of Latin.

www.vesalius-fabrica.com

www.karger.com/gat_Guidelines

© 2013 S. Karger AG, Basel

The Guidelines for Authors are available at:

www.karger.com/gat_Guidelines
**Subscription Rates:** Subscriptions run for a full calendar year. Prices are given per year.

| Subscription Type | Print or Online | Print+Online combined |
|-------------------|-----------------|-----------------------|
| CHF 260.–         | EUR 213.–       | EUR 308.–             |
| USD 260.00        | USD 208.00      | USD 296.00            |
| **postage and handling** | **added to print and print+online** | **EUR 49.00** |
| CHF 29.60 Europe, CHF 43.20 Overseas | EUR 39.20 | USD 49.00 |

**Institutional subscription:**

| Print or Online | Print+Online combined |
|-----------------|-----------------------|
| CHF 1500.–      | EUR 1500.–            |
| EUR 1230.–      | USD 1500.00           |
| USD 1500.00     | USD 1650.00           |
| **postage and handling** | **added to print and print+online** | **EUR 49.00** |
| CHF 37.– Europe, CHF 54.– Overseas | EUR 54.- | USD 64.00 |

**Back Volumes and Single Issues:** Information on availability and prices of single print issues and print or electronic back volumes can be obtained from Customer Service at service@karger.com.

**Bibliographic Indices:** This journal is regularly listed in bibliographic services.

**Photocopying:** This journal has been registered with the Copyright Clearance Center (CCC), as indicated by the code appearing on the first page of each article. For readers in the US, this code signals consent for copying of articles for personal or internal use, or for the personal or internal use of specific clients, provided that the stated fee is paid per copy directly to Copyright Clearance Center Inc., 222 Rosewood Drive Danvers, MA 01923 (USA). A copy of the first page of the article must accompany payment. Consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. In these cases, specific written permission must be obtained from the copyright owner, S. Karger AG, P.O. Box CH–4009 Basel (Switzerland).
Contents

See the journal website for contents
Indocyanine green (ICG) fluorescence has been used for imaging purposes for more than half a century; first employed by ophthalmologists for visualizing the retinal artery in the late 1960s, the application of ICG fluorescence imaging has since been continuously expanded. Recently, advances in imaging technologies have led to renewed attention regarding the use of ICG in the field of hepatobiliary surgery, as a new tool for visualizing the biliary tree and liver tumors.

This book introduces cutting-edge knowledge about fluorescence imaging techniques using both ICG and other new promising chemicals. After an introductory chapter on the history and basic technique of fluorescence imaging for hepatobiliary-pancreatic surgery, various clinical applications of ICG fluorescence imaging are discussed. These range from the identification of various malignancies to the use of imaging in surgery. The last part of this publication is dedicated to an outlook on near-future technology.
Liver Cancer has a very high prevalence among cancers in general and is one of the most common causes of death worldwide. Based on these facts, the journal Liver Cancer serves the growing need to better understand the causes, mechanisms and therapy of the malignancy. It provides the international community of researchers and clinicians with a platform for their research results, focusing on molecular carcinogenesis, prevention, surveillance, diagnosis and treatment, including molecular targeted therapy, of the disease.

Liver Cancer publishes clinical and translational research related to the field of liver cancer in both humans and experimental models in the form of original and review articles.

Selected Contributions
- Biomarkers: Evaluation of Screening for and Early Diagnosis of Hepatocellular Carcinoma in Japan and China: Song, P.; Gao, J.; Inagaki, Y.; Kokudo, N.; Hasegawa, K.; Sugawara, Y.; Tang, W. (Tokyo)
- Adjuvant Therapy after Curative Resection for Hepatocellular Carcinoma Associated with Hepatitis Virus: Kubo, S.; Takemura, S.; Sakata, C.; Urata, Y.; Uenishi, T. (Osaka)
- Portal Venous Embolization for Hepatocellular Carcinoma: Shindoh, J.; Tzeng, C.-W.D.; Vauthey, J. (Houston, Tex.)
- Liver Transplantation for Hepatocellular Carcinoma: An Appraisal of Current Controversies: Cheah, Y.L.; Chow, P.K.H. (Singapore)
- Immunotherapeutic Approaches to Hepatocellular Carcinoma Treatment: Miampen, A.G.; Dong, H.; Roberts, L.R. (Rochester, Minn.)
- Why Does Every Hepatocellular Carcinoma Clinical Trial Using Molecular Targeted Agents Fail?: Kudo, M. (Osaka)
- Emerging Signaling Pathways in Hepatocellular Carcinoma: Moeini, A.; Cornella, H.; Villanueva, A. (Barcelona/Madrid)

Submission of papers
The editor cordially invites you to submit your original or clinical review paper to Liver Cancer. Manuscripts written in English should be submitted to the Editorial Assistant, Ms. Tanja Sebuk: t.sebuk@karger.ch
Comprehensive coverage of selected topics

Digestive Diseases
Clinical Reviews

Editor-in-Chief
P. Malfertheiner,
Magdeburg

Official Journal of
European Association for
Gastroenterology, Endoscopy
and Nutrition

Recent Topics
- Interfaces and Controversies in Gastroenterology / Challenges of Liver Cirrhosis and Tumors: Prevent It, Treat It, Manage Consequences ISBN 978–3–18–02382–4
- Viral Hepatitis and Hepatocellular Carcinoma: Update in 2012 ISBN 978–3–18–02386–5
- Inflammation and Cancer ISBN 978–3–18–02249–8
- Revisiting IBD Management: Dogmas to Be Challenged ISBN 978–3–18–02185–1
- Metabolic and Autoimmune Diseases of the Digestive System ISBN 978–3–18–02145–5
- Diverticular Disease: A Fresh Approach to a Neglected Disease ISBN 978–3–18–02185–8
- Gut Microbiota: The Forgotten Organ ISBN 978–3–18–02185–8
- Acid Inhibition and Peptic Ulcer — 100 Years of Carl Schwarz’s Dictum: No Acid — No Ulcer ISBN 978–3–18–02185–8
- Liver and Immunology ISBN 978–3–18–02145–5
- Molecular Targeted Therapy for Hepatocellular Carcinoma: Bench to Bedside ISBN 978–3–18–02411–6
- Environment and Lifestyle — Effects on Disorders of the Digestive Tract ISBN 978–3–18–02386–5
- Bile Acids as Metabolic Integrators and Therapeutics ISBN 978–3–18–02386–5
- Liver and Pancreatic Diseases: Consequences of Chronic Alcoholic Consumption ISBN 978–3–18–02386–5
- Endoscopy Live Berlin 2011 — Intestinal Disease Meeting ISBN 978–3–18–02185–8
- From Chronic Inflammation to Cancer ISBN 978–3–18–02185–8

Each issue of this journal is dedicated to a special topic of current interest, covering both clinical and basic science topics in gastrointestinal function and disorders. The contents of each issue are comprehensive and reflect the state of the art, featuring editorials, reviews, mini reviews and original papers. These individual contributions encompass a variety of disciplines including all fields of gastroenterology. Digestive Diseases bridges the communication gap between advances made in the academic setting and their application in patient care. The journal is a valuable service for clinicians, specialists and physicians-in-training.

More information at
www.karger.com/ddi
- Pay-per-View and Subscriber Access to Full Text
- Full Table of Contents
- Full Editorial Board
- Free Abstracts and Selected Articles
- Online Sample Issue
- Submission/Guidelines for Authors
- Subscription Details
- Free Alert Service
- Online Library Recommendation

Digestive Diseases
2014 Volume 32
6 issues per volume
Language: English
ISSN 0257–2753 (print)
ISSN 1421–9875 (online)

Listed in bibliographic services, including Current Contents®, MEDLINE, Biological Abstracts
The discovery of proton pump inhibitors (PPIs) and their development over the years has dramatically changed the management of acid-related diseases. Today, the therapeutic domain of PPIs ranges from relief of symptoms to cure of mucosal lesions in the upper gastrointestinal tract. PPIs are among the most widely sold drugs in the world and are now even available as over-the-counter medication.

This publication presents the experience of the last 25 years during which PPIs have become of enormous value in gastroenterology. The authors provide an update on a variety of subjects, starting with an introduction to the discovery and development of PPIs. This is followed by chapters on pharmacokinetics, pharmacodynamics and pharmacogenetics, gastroesophageal reflux disease, gastroprotection, Helicobacter pylori eradication treatment, peptic ulcer disease, functional dyspepsia, acid suppression in exocrine pancreatic insufficiency, and gastrointestinal and systemic side effects.

Readers who are interested in a current overview of PPIs and their various applications will find this book of great value.

Contents
Preface: Chiba, T.; Malfertheiner, P.; Satoh, H.
Discovery and Development of Proton Pump Inhibitors: Satoh, H.
Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Proton Pump Inhibitors: Furuta, T.; Sugimoto, M.; Shirai, N.
Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Bruley des Varannes, S.
Proton Pump Inhibitors in Gastroprotection: Prevention and Healing of Nonsteroidal Anti-Inflammatory Drug-, Aspirin-, and Cyclooxygenase-2 Inhibitor-Induced Gastroduodenal Lesions: Kyaw, M.H.; Chan, F.K.L.
Proton Pump Inhibitors: Key Ingredients in Helicobacter pylori Eradication Treatment: Sugiyama, T.
Proton Pump Inhibitor Management in Bleeding Peptic Ulcer Disease: Sung, J.
Proton Pump Inhibitors in Functional Dyspepsia: Miwa, H.
Role of Acid Suppression in Exocrine Pancreatic Insufficiency: A Therapeutic Principle: Waldthaler, A.; Schütte, K.; Malfertheiner, P.
Proton Pump Inhibitors and Gastrointestinal Side Effects: Nakamura, S.; Seno, H.; Chiba, T.
Administration of Proton Pump Inhibitors and Risk of Systemic Side Effects: Kinoshita, Y.; Ishihara, S.
Gastric Cancer is the number 2 cancer death cause in the world. However, there is a great regional difference in incidence, the highest rate being found in men in northeast Asia (Japan, Korea and China). Just as incidence varies, there are also differences in screening programs and treatment strategies between Eastern and Western countries. In this publication, experts in the field of gastric cancer from both the East and the West impart their evidence-based view as well as express their expert opinion on topics that are still being discussed. These include lymph node dissection, sentinel node navigation surgery, adjuvant and neoadjuvant therapies, laparoscopic gastrectomy, various methods of gastric cancer staging, underlying molecular mechanisms, and palliative treatment. 

Contents

Preface
• Current Diagnosis and Treatment of Gastric Cancer: Where East Meets West: Hartgrink, H.H.; Kodera, Y.

Editorial
• Surgery for Gastric Cancer: Has the East versus West Issue Been Solved? Kodera, Y.
• Lymph Node Dissection in Resectable Advanced Gastric Cancer: de Steur, W.O.; Dikken, J.L.; Hartgrink, H.H.
• Sentinel Node Navigation Surgery in Patients with Early Gastric Cancer: Takeuchi, H.; Kitagawa, Y.
• (Neo)-Adjuvant Chemotherapy for Adenocarcinomas of the Gastroesophageal Junction and the Stomach in the West: Wilke, H.; Lordick, F.; Meyer, H.-J.; Stahl, M.
• Overview of Adjuvant and Neoadjuvant Therapy for Resectable Gastric Cancer in the East: Fujitani, K.

Editorial
• The New Era of Gastric Cancer in the East and West: Have Our Approaches Harmonized? Strong, V.E.
• Laparoscopic Gastrectomy for Gastric Cancer: Lee, H.-J.; Yang, H.-K.
• Gastric Cancer Staging with Radiologic Imaging Modalities and UICC Staging System: Ahn, H.S.; Kim, S.H.; Kodera, Y.; Yang, H.-K.
• Gastric Cancer Pathology and Underlying Molecular Mechanisms: Grabsch, H.H.; Tan, P.
• Follow-Up: The Evidence: D’Ugo, D.; Biondi, A.; Tufo, A.; Persiani, R.
• Treatment Approaches to Esophagogastric Junction Tumors: Kurokawa, Y.; Sasako, M.; Doki, Y.
• Palliative Treatment and the Role of Surgical Resection in Gastric Cancer: Karpeh Jr., M.S.
Focus on Gastrointestinal Tumors
Fang, J.-Y. (Shanghai); Malfertheiner, P. (Magdeburg)

Current Perspective on the Pathogenesis of Small Intestinal Neuroendocrine Tumors: Progress in Biomarkers and Molecular Events
Chen, Y.-X.; Fang, J.-Y. (Shanghai)

Small Bowel Neoplasias: Current Options for Diagnosis, Staging and Therapeutic Management
Fry, L.C. (Bottrop/Birmingham, Ala.); Gutierrez, J.P. (Birmingham, Ala.); Jovanovic, I. (Belgrade); Mönkemüller, K. (Birmingham, Ala.)

Colorectal Cancer: Basic and Translational Research
Zhou, J.J.; Zheng, S. (Hangzhou)

Current Options for the Diagnosis, Staging and Therapeutic Management of Colorectal Cancer
Nakayama, G.; Tanaka, C.; Kodera, Y. (Nagoya)

Pancreatic Cancer: Clinical Significance of Biomarkers
Ohuchida, K.; Ohtsuka, T.; Mizumoto, K.; Hashizume, M.; Tanaka, M. (Fukuoka)

Pancreatic Cancer: Current Options for Diagnosis, Staging and Therapeutic Management
Hartwig, W.; Büchler, M.W. (Heidelberg)